EGR1 (Early Growth Response 1)

This research highlights the pivotal role of TOE1 in HCC, indicating its promise as a novel target for early detection, therapeutic strategies, immunological intervention, and prognosis assessment in HCC. These findings provide fresh perspectives for precision medicine in the context of HCC.

The HCC cells HepG2 and SNU449 were treated with five drugs, namely, dimethyl sulfoxide, AZ-628, SU-5402, TG-101209, and SPP-86, combined with donafenib to determine half-maximal inhibitory concentration values...Ferrous ion (Fe2+) and reactive oxygen species levels were measured after Erastin/RSL3 induction...In vivo experiments demonstrated a combined anti-tumor efficacy of AZ-628 and donafenib in HCC models (P < 0.0001). The findings of this study reveal a new combination therapy targeting the TK pathway for the treatment of HCC and provide a theoretical foundation for addressing donafenib resistance.

In addition, EV71 infection reduces cellular GSH and GPX4 expression, promotes ROS production, and decreases cell viability. These findings reveal significant transcriptional reprogramming of ferroptosis-associated genes during EV71 infection, highlighting a potential role for this pathway that requires direct experimental validation.

Together, these findings reveal a novel mechanism where Riluzole promotes apoptosis through upregulation of EGR1 , which then cooperates with YAP/p73 to activate Bax expression. These insights establish Riluzole as a promising therapeutic intervention for OS treatment through modulation of the EGR1 /Yap/p73/Bax signaling axis.

This study identified and validated prognostic biomarkers in HCC that effectively predict patient survival rates and immune infiltration characteristics. These findings provide a potential foundation for precision medicine strategies in HCC, offering novel insights into the tumor-immune microenvironment and its clinical implications.

Notably, pimozide exhibited anti-tumor effects as a monotherapy and in combination with paclitaxel at clinically relevant doses. While tumor volume reduction in the combination group was not statistically greater than that in the monotherapy group, fluorescence immunohistochemistry revealed a marked decrease in undifferentiated tumor cells, indicating enhanced therapeutic effects of combination treatment. Taken together, these findings indicate that pimozide is a promising candidate for repurposing as a novel therapeutic agent against HNSCC.

Cells with active TGF-β signaling stabilize mouse Malat1 while the same signaling destabilizes zebrafish malat1. Our findings uncover a previously unknown role of malat1/Egr1 axis as a crucial regulator of retina regeneration, shedding light on its possible influence on the different regenerative abilities of vertebrates.

Interestingly, JQ1 (a specific BET inhibitor) triggered cell cycle arrest only in sensitive cells when used alone while addition of mTOR inhibitors extended this antiproliferative effect to BET-resistant cells as well...This study validates the combined use of BET and mTOR inhibitors as a promising treatment strategy for AML, capable of overcoming resistance and enhancing therapeutic outcomes. Furthermore, our investigation also highlights EGR1 not only as a biomarker of treatment response, but also as a potential target for future therapeutic interventions, offering valuable insights for patient management.

Moreover, PDK1 inhibition increased the therapeutic effect of APR-246 on TP53 mutant breast cancer in xenograft tumors. Our results suggested that intervention of PDK1 could potentially emerge as a new therapeutic strategy to impede the progression of TP53 mutant breast cancer.

Notably, early growth response 1 (EGR1) expression was elevated in SH3BGRL2-silenced PDCs, suggesting that SH3BGRL2 may suppress ESCC proliferation by blocking the EGR1 pathway. SH3BGRL2 acts as a key tumor suppressor and prognostic determinant in ESCC, which represents a novel insight into the pathogenesis of this malignancy.

IL-4 and its upstream transcription factors Jun, Fos, and Egr1 may be associated with FS occurrence and development. Moreover, dupilumab appeared to mitigate the symptoms of FS and modulate the associated immune response by blocking the IL-4 receptor.